FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024987400> ?p ?o ?g. }

• W2024987400 endingPage "14" @default.
• W2024987400 startingPage "8" @default.
• W2024987400 abstract "Article Abstract Objective: This article summarizes the US Food and Drug Administration's (FDA's ) review of the New Drug Application for vortioxetine, especially the clinical efficacy and safety data. It emphasizes the issues that were important to the FDA's approval decision, particularly the difference in the effective dose in domestic and foreign studies, and notes several new labeling features, specifically, description of time course of treatment response and detailed sexual dysfunction evaluation. Data Sources: The data sources were the original raw data sets for all clinical trials included in the development program for vortioxetine, as well as the sponsor's original analyses of these data. Data were available from 51 human trials involving vortioxetine, and included a total of 7,666 healthy volunteers and patients with a diagnosis of major depressive disorder (MDD) or generalized anxiety disorder who were exposed to at least 1 dose of vortioxetine for a total of 2,743 patient-years. Results: Vortioxetine was effective in treating MDD in the United States at a dose of 20 mg/d. The recommended starting dose is 10 mg once daily without regard to food, with increase to 20 mg/d if the 10 mg/d dose is tolerated. For patients who do not tolerate 20 mg/d, 10 mg/d can be used and 5-mg/d dose can be considered. Vortioxetine can be discontinued abruptly, but it is recommended that doses of 15 mg/d or 20 mg/d be reduced to 10 mg/d for 1 week prior to full discontinuation to avoid potential withdrawal symptoms. Although the non-US maintenance study showed that maintenance doses of 5 to 10 mg/d were effective, a clinical judgment needs to be made to decide the maintenance dose in the United States. The applicant has agreed to conduct a US maintenance dose-response study covering the US-approved dose range. Vortioxetine's adverse event profile is similar to that of other selective serotonin reuptake inhibitors (SSRIs). Nausea is the most common adverse event and is dose dependent. No dose adjustment is needed based on age, gender, or the presence of renal or mild to moderate hepatic impairment. The maximum recommended dose is 10 mg/d in known cytochrome P450 2D6 poor metabolizers. Conclusions: Vortioxetine is a new treatment for MDD, and its adverse event profile is similar to that of other SSRIs." @default.
• W2024987400 created "2016-06-24" @default.
• W2024987400 creator A5002326010 @default.
• W2024987400 creator A5002523253 @default.
• W2024987400 creator A5003065611 @default.
• W2024987400 creator A5005327375 @default.
• W2024987400 creator A5005350930 @default.
• W2024987400 creator A5016141223 @default.
• W2024987400 creator A5019852114 @default.
• W2024987400 creator A5035843654 @default.
• W2024987400 creator A5051452058 @default.
• W2024987400 creator A5065637954 @default.
• W2024987400 creator A5070600575 @default.
• W2024987400 creator A5090399372 @default.
• W2024987400 date "2014-11-11" @default.
• W2024987400 modified "2023-10-06" @default.
• W2024987400 title "The US Food and Drug Administration’s Perspective on the New Antidepressant Vortioxetine" @default.
• W2024987400 cites W1963643315 @default.
• W2024987400 cites W1973049100 @default.
• W2024987400 cites W1987560991 @default.
• W2024987400 cites W2000737116 @default.
• W2024987400 cites W2011606125 @default.
• W2024987400 cites W2033826788 @default.
• W2024987400 cites W2034337210 @default.
• W2024987400 cites W2048026164 @default.
• W2024987400 cites W2054766240 @default.
• W2024987400 cites W2059274457 @default.
• W2024987400 cites W2061669920 @default.
• W2024987400 cites W2066283885 @default.
• W2024987400 cites W2071735605 @default.
• W2024987400 cites W2084671514 @default.
• W2024987400 cites W2128693064 @default.
• W2024987400 cites W2153613681 @default.
• W2024987400 cites W2160047406 @default.
• W2024987400 cites W2170015439 @default.
• W2024987400 doi "https://doi.org/10.4088/jcp.14r09164" @default.
• W2024987400 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25562777" @default.
• W2024987400 hasPublicationYear "2014" @default.
• W2024987400 type Work @default.
• W2024987400 sameAs 2024987400 @default.
• W2024987400 citedByCount "30" @default.
• W2024987400 countsByYear W20249874002015 @default.
• W2024987400 countsByYear W20249874002016 @default.
• W2024987400 countsByYear W20249874002017 @default.
• W2024987400 countsByYear W20249874002018 @default.
• W2024987400 countsByYear W20249874002019 @default.
• W2024987400 countsByYear W20249874002020 @default.
• W2024987400 countsByYear W20249874002021 @default.
• W2024987400 countsByYear W20249874002022 @default.
• W2024987400 countsByYear W20249874002023 @default.
• W2024987400 crossrefType "journal-article" @default.
• W2024987400 hasAuthorship W2024987400A5002326010 @default.
• W2024987400 hasAuthorship W2024987400A5002523253 @default.
• W2024987400 hasAuthorship W2024987400A5003065611 @default.
• W2024987400 hasAuthorship W2024987400A5005327375 @default.
• W2024987400 hasAuthorship W2024987400A5005350930 @default.
• W2024987400 hasAuthorship W2024987400A5016141223 @default.
• W2024987400 hasAuthorship W2024987400A5019852114 @default.
• W2024987400 hasAuthorship W2024987400A5035843654 @default.
• W2024987400 hasAuthorship W2024987400A5051452058 @default.
• W2024987400 hasAuthorship W2024987400A5065637954 @default.
• W2024987400 hasAuthorship W2024987400A5070600575 @default.
• W2024987400 hasAuthorship W2024987400A5090399372 @default.
• W2024987400 hasConcept C118552586 @default.
• W2024987400 hasConcept C126322002 @default.
• W2024987400 hasConcept C15744967 @default.
• W2024987400 hasConcept C2778034309 @default.
• W2024987400 hasConcept C2779177272 @default.
• W2024987400 hasConcept C2780035454 @default.
• W2024987400 hasConcept C2780051608 @default.
• W2024987400 hasConcept C2780733359 @default.
• W2024987400 hasConcept C3018890749 @default.
• W2024987400 hasConcept C535046627 @default.
• W2024987400 hasConcept C558461103 @default.
• W2024987400 hasConcept C71924100 @default.
• W2024987400 hasConcept C98274493 @default.
• W2024987400 hasConceptScore W2024987400C118552586 @default.
• W2024987400 hasConceptScore W2024987400C126322002 @default.
• W2024987400 hasConceptScore W2024987400C15744967 @default.
• W2024987400 hasConceptScore W2024987400C2778034309 @default.
• W2024987400 hasConceptScore W2024987400C2779177272 @default.
• W2024987400 hasConceptScore W2024987400C2780035454 @default.
• W2024987400 hasConceptScore W2024987400C2780051608 @default.
• W2024987400 hasConceptScore W2024987400C2780733359 @default.
• W2024987400 hasConceptScore W2024987400C3018890749 @default.
• W2024987400 hasConceptScore W2024987400C535046627 @default.
• W2024987400 hasConceptScore W2024987400C558461103 @default.
• W2024987400 hasConceptScore W2024987400C71924100 @default.
• W2024987400 hasConceptScore W2024987400C98274493 @default.
• W2024987400 hasIssue "01" @default.
• W2024987400 hasLocation W20249874001 @default.
• W2024987400 hasLocation W20249874002 @default.
• W2024987400 hasOpenAccess W2024987400 @default.
• W2024987400 hasPrimaryLocation W20249874001 @default.
• W2024987400 hasRelatedWork W1273990964 @default.
• W2024987400 hasRelatedWork W1572757696 @default.
• W2024987400 hasRelatedWork W1718269887 @default.
• W2024987400 hasRelatedWork W22533895 @default.

• next